Genmab A/S
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervic… Read more
Genmab A/S (GNMSF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.093x
Based on the latest financial reports, Genmab A/S (GNMSF) has a cash flow conversion efficiency ratio of 0.093x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($536.00 Million) by net assets ($5.75 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Genmab A/S - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how Genmab A/S's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Genmab A/S Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genmab A/S ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jack Henry & Associates Inc
NASDAQ:JKHY
|
0.069x |
|
UltraTech Cement Limited
PINK:UCLQF
|
0.021x |
|
Five Below Inc
NASDAQ:FIVE
|
-0.041x |
|
Straumann Holding AG
PINK:SAUHF
|
0.106x |
|
AP Moeller - Maersk A/S A
PINK:AMKAF
|
0.050x |
|
XCMG Construction Machinery Co Ltd
SHE:000425
|
0.035x |
|
Companhia de Saneamento Básico do Estado de São Paulo - SABESP
F:SAJA
|
0.074x |
|
WEG S.A
SA:WEGE3
|
0.097x |
Annual Cash Flow Conversion Efficiency for Genmab A/S (2002–2024)
The table below shows the annual cash flow conversion efficiency of Genmab A/S from 2002 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $36.70 Billion | $7.77 Billion | 0.212x | -9.30% |
| 2023-12-31 | $31.61 Billion | $7.38 Billion | 0.233x | +62.82% |
| 2022-12-31 | $27.28 Billion | $3.91 Billion | 0.143x | +42.85% |
| 2021-12-31 | $22.20 Billion | $2.23 Billion | 0.100x | -70.16% |
| 2020-12-31 | $19.12 Billion | $6.43 Billion | 0.336x | +256.43% |
| 2019-12-31 | $14.05 Billion | $1.33 Billion | 0.094x | -25.45% |
| 2018-12-31 | $8.01 Billion | $1.01 Billion | 0.127x | -50.02% |
| 2017-12-31 | $6.27 Billion | $1.59 Billion | 0.253x | +273.12% |
| 2016-12-31 | $4.83 Billion | $327.72 Million | 0.068x | -23.99% |
| 2015-12-31 | $3.49 Billion | $311.45 Million | 0.089x | +36.87% |
| 2014-12-31 | $2.03 Billion | $132.67 Million | 0.065x | +133.63% |
| 2013-12-31 | $659.52 Million | $-128.00 Million | -0.194x | -204.86% |
| 2012-12-31 | $383.19 Million | $70.92 Million | 0.185x | +120.59% |
| 2011-12-31 | $486.42 Million | $-437.23 Million | -0.899x | -462.02% |
| 2010-12-31 | $1.08 Billion | $268.17 Million | 0.248x | +156.50% |
| 2009-12-31 | $1.30 Billion | $-570.06 Million | -0.439x | -87.36% |
| 2008-12-31 | $2.19 Billion | $-513.33 Million | -0.235x | -233.68% |
| 2007-12-31 | $2.88 Billion | $505.90 Million | 0.175x | +174.30% |
| 2006-12-31 | $1.61 Billion | $-379.62 Million | -0.236x | -26.62% |
| 2005-12-31 | $1.12 Billion | $-208.64 Million | -0.186x | +40.10% |
| 2004-12-31 | $1.18 Billion | $-367.70 Million | -0.311x | -11.87% |
| 2003-12-31 | $1.09 Billion | $-302.36 Million | -0.278x | -26.30% |
| 2002-12-31 | $1.40 Billion | $-308.32 Million | -0.220x | -- |